Generation of a homozygous CIITA knockout iPS cell line using the CRISPR-Cas9 system
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved..
Human induced pluripotent stem cells (iPSCs) have great promise in regenerative medicine. However, several limitations, including immune-incompatibility, have raised concerns regarding their clinical application. Recent studies have shown that human iPSCs and their derivatives lose their immunogenicity when major histocompatibility complex (MHC) class I and II genes are inactivated and CD47 is over-expressed. In this study, we used CRISPR-Cas9 technology to generate an isogenic iPSC line with a homozygous frameshift mutation in the MHC II transactivator (CIITA) gene. The CIITA-/- iPSCs exhibit typical morphology of pluripotent cells, normal karyotype, expression of pluripotency markers and differentiation capacity in the three germ layers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Stem cell research - 57(2021) vom: 19. Dez., Seite 102580 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Romano, Elena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 21.12.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.scr.2021.102580 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332282422 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332282422 | ||
| 003 | DE-627 | ||
| 005 | 20231227135115.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.scr.2021.102580 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1234.xml |
| 035 | |a (DE-627)NLM332282422 | ||
| 035 | |a (NLM)34688128 | ||
| 035 | |a (PII)S1873-5061(21)00427-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Romano, Elena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Generation of a homozygous CIITA knockout iPS cell line using the CRISPR-Cas9 system |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Human induced pluripotent stem cells (iPSCs) have great promise in regenerative medicine. However, several limitations, including immune-incompatibility, have raised concerns regarding their clinical application. Recent studies have shown that human iPSCs and their derivatives lose their immunogenicity when major histocompatibility complex (MHC) class I and II genes are inactivated and CD47 is over-expressed. In this study, we used CRISPR-Cas9 technology to generate an isogenic iPSC line with a homozygous frameshift mutation in the MHC II transactivator (CIITA) gene. The CIITA-/- iPSCs exhibit typical morphology of pluripotent cells, normal karyotype, expression of pluripotency markers and differentiation capacity in the three germ layers | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Trionfini, Piera |e verfasserin |4 aut | |
| 700 | 1 | |a Giampietro, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Benigni, Ariela |e verfasserin |4 aut | |
| 700 | 1 | |a Tomasoni, Susanna |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stem cell research |d 2007 |g 57(2021) vom: 19. Dez., Seite 102580 |w (DE-627)NLM18622009X |x 1876-7753 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2021 |g day:19 |g month:12 |g pages:102580 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.scr.2021.102580 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2021 |b 19 |c 12 |h 102580 | ||